Angelica Benavides-Serrato
Overview
Explore the profile of Angelica Benavides-Serrato including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saunders J, Kumar S, Benavides-Serrato A, Holmes B, Benavides K, Bashir M, et al.
J Neurooncol
. 2023 May;
163(1):207-218.
PMID: 37162666
Introduction: HGF/c-MET signaling is a significant driver of glioblastoma (GBM) growth and disease progression. Unfortunately, c-MET targeted therapies have been found to be largely ineffective suggesting additional redundant mechanisms of...
2.
Benavides-Serrato A, Saunders J, Kumar S, Holmes B, Benavides K, Bashir M, et al.
Cancer Lett
. 2023 Apr;
562:216178.
PMID: 37061119
A major mechanism conferring resistance to mTOR inhibitors is activation of a salvage pathway stimulating internal ribosome entry site (IRES)-mediated mRNA translation, driving the synthesis of proteins promoting resistance of...
3.
Holmes B, Benavides-Serrato A, Saunders J, Kumar S, Nishimura R, Gera J
Neoplasia
. 2021 Aug;
23(9):951-965.
PMID: 34343821
The Hippo and mTOR signaling cascades are major regulators of cell growth and division. Aberrant regulation of these pathways has been demonstrated to contribute to gliomagenesis and result in enhanced...
4.
Saunders J, Holmes B, Benavides-Serrato A, Kumar S, Nishimura R, Gera J
J Neurooncol
. 2021 Jan;
152(2):217-231.
PMID: 33511508
Introduction: Recent studies have suggested that dysregulated Hippo pathway signaling may contribute to glioblastoma proliferation and invasive characteristics. The downstream effector of the pathway, the Yes-associated protein (YAP) oncoprotein, has...
5.
Benavides-Serrato A, Saunders J, Holmes B, Nishimura R, Lichtenstein A, Gera J
Int J Mol Sci
. 2020 Jan;
21(1).
PMID: 31948038
Internal ribosome entry site (IRES)-mediated protein synthesis has been demonstrated to play an important role in resistance to mechanistic target of rapamycin (mTOR) targeted therapies. Previously, we have demonstrated that...
6.
Holmes B, Benavides-Serrato A, Saunders J, Landon K, Schreck A, Nishimura R, et al.
J Neurooncol
. 2019 Sep;
145(1):11-22.
PMID: 31473880
Introduction: Clinical trials directed at mechanistic target of rapamycin (mTOR) inhibition have yielded disappointing results in glioblastoma (GBM). A major mechanism of resistance involves the activation of a salvage pathway...
7.
Benavides-Serrato A, Lee J, Holmes B, Landon K, Bashir T, Jung M, et al.
PLoS One
. 2019 Feb;
14(2):e0212160.
PMID: 30726300
[This corrects the article DOI: 10.1371/journal.pone.0176599.].
8.
Benavides-Serrato A, Lee J, Holmes B, Landon K, Bashir T, Jung M, et al.
PLoS One
. 2017 Apr;
12(4):e0176599.
PMID: 28453552
A small molecule which specifically blocks the interaction of Rictor and mTOR was identified utilizing a high-throughput yeast two-hybrid screen and evaluated as a potential inhibitor of mTORC2 activity in...
9.
Holmes B, Lee J, Landon K, Benavides-Serrato A, Bashir T, Jung M, et al.
J Biol Chem
. 2016 May;
291(27):14146-14159.
PMID: 27226604
Our previous work has demonstrated an intrinsic mRNA-specific protein synthesis salvage pathway operative in glioblastoma (GBM) tumor cells that is resistant to mechanistic target of rapamycin (mTOR) inhibitors. The activation...
10.
Artinian N, Cloninger C, Holmes B, Benavides-Serrato A, Bashir T, Gera J
J Biol Chem
. 2015 May;
290(32):19387-401.
PMID: 25998128
The mechanistic target of rapamycin (mTOR) and Hippo signaling pathways are two major signaling cascades that coordinately regulate cell growth and proliferation. Dysregulation of these pathways plays a critical role...